Indole Derivatives Modulate CFTR Protein Folding and Trafficking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ABC transporter-mediated diseases, such as cystic fibrosis, are limited in effectiveness due to defects in protein folding and trafficking, leading to reduced anion transport and impaired ion and fluid balance.
Innovation Solution
Development of compounds that modulate ABC transporter activity, particularly CFTR, using specific chemical formulas that can increase or decrease the activity of CFTR, thereby addressing the underlying defects in protein trafficking and function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for ABC transporter-mediated diseases are used, then disease management is maintained, but treatment effectiveness is limited due to defects in protein folding and trafficking
Solution Approach 1:
The patent introduces CFTR modulators as intermediary compounds that mediate between the defective CFTR protein and normal function. These modulators act as molecular chaperones or functional regulators that correct protein folding defects and restore trafficking without requiring complete protein synthesis replacement, thereby improving treatment effectiveness while addressing the root cause of the disease
Solution Approach 2:
The invention employs chemical compounds with specific molecular structures (formula I and II) that change the physical-chemical parameters of the CFTR protein environment. By altering parameters such as protein conformation, membrane localization, and channel gating properties, these modulators restore CFTR function despite genetic mutations, enhancing treatment reliability and adaptability
2Reliability
If CFTR activity is modulated to improve anion transport, then ion and fluid balance is restored, but the complexity of identifying effective compounds increases
Solution Approach 1:
The patent segments the CFTR modulation problem into distinct functional categories represented by formula I (potentially targeting folding/trafficking) and formula II (potentially targeting channel activity). This segmentation allows systematic development of compounds with specific mechanisms of action, reducing the overall complexity by breaking down the identification process into manageable structural classes
Solution Approach 2:
The disclosed compound classes represent universal structures that can address multiple CFTR-related defects through a single molecular framework. These modulators can potentially correct various mutation types (folding defects, trafficking issues, channel gating problems) using the same basic chemical scaffold, thereby restoring ion and fluid balance across different disease presentations without requiring completely different compound classes for each case
Data Source
AI summary
Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.